Alzamend Neuro (ALZN) Competitors $0.66 0.00 (-0.69%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. CING, UPXI, EQ, GLYC, COCP, BFRG, SNYR, LPTX, EDSA, and BIVIShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Cingulate (CING), Upexi (UPXI), Equillium (EQ), GlycoMimetics (GLYC), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Synergy CHC Corp. (Uplisting) (SNYR), Leap Therapeutics (LPTX), Edesa Biotech (EDSA), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Cingulate Upexi Equillium GlycoMimetics Cocrystal Pharma Bullfrog AI Synergy CHC Corp. (Uplisting) Leap Therapeutics Edesa Biotech BioVie Alzamend Neuro (NASDAQ:ALZN) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Does the MarketBeat Community believe in ALZN or CING? Cingulate received 5 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 80.00% of users gave Cingulate an outperform vote. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes7100.00% Underperform VotesNo VotesCingulateOutperform Votes1280.00% Underperform Votes320.00% Which has higher earnings and valuation, ALZN or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/ACingulateN/AN/A-$23.53M-$14.64-0.29 Is ALZN or CING more profitable? Alzamend Neuro's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Cingulate N/A -570.20%-236.15% Does the media prefer ALZN or CING? In the previous week, Cingulate had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 4 mentions for Cingulate and 3 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.29 beat Cingulate's score of 0.58 indicating that Alzamend Neuro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ALZN or CING? Alzamend Neuro presently has a consensus target price of $20.00, suggesting a potential upside of 2,930.30%. Cingulate has a consensus target price of $30.67, suggesting a potential upside of 628.42%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, ALZN or CING? Alzamend Neuro has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.87, suggesting that its share price is 187% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ALZN or CING? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryAlzamend Neuro beats Cingulate on 8 of the 14 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.36M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E RatioN/A7.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book-0.196.516.774.25Net Income-$9.95M$143.21M$3.22B$248.23M7 Day Performance-3.66%3.97%3.26%3.29%1 Month Performance-37.74%0.37%0.02%2.42%1 Year Performance-90.72%2.60%18.01%5.54% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.4973 of 5 stars$0.66-0.7%$20.00+2,930.3%-90.7%$4.39MN/A0.004Short Interest ↓Positive NewsCINGCingulate2.4774 of 5 stars$4.35+1.2%$30.67+605.0%+350.8%$17.14MN/A-0.3020Short Interest ↑UPXIUpexi0.9669 of 5 stars$12.92-16.7%N/A+9.4%$17.07M$18.63M0.00130Short Interest ↑Gap DownHigh Trading VolumeEQEquillium2.7926 of 5 stars$0.46+4.5%$3.00+555.0%-71.8%$16.88M$41.10M-3.2740Upcoming EarningsShort Interest ↓Positive NewsGap DownGLYCGlycoMimetics2.0925 of 5 stars$0.26-0.2%N/A-86.0%$16.81M$10,000.00-0.4450Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap UpCOCPCocrystal Pharma2.4954 of 5 stars$1.65-3.5%$7.00+324.2%-4.4%$16.78MN/A-0.8910Gap UpBFRGBullfrog AI0.4742 of 5 stars$1.77-4.3%N/A-43.6%$16.67M$60,000.00-2.084Short Interest ↑SNYRSynergy CHC Corp. (Uplisting)3.531 of 5 stars$1.92+19.3%$10.00+420.8%N/A$16.46M$34.83M0.0040Gap DownLPTXLeap Therapeutics2.6186 of 5 stars$0.40-1.1%$4.92+1,142.8%-86.5%$16.32MN/A-0.2040Gap UpEDSAEdesa Biotech3.0965 of 5 stars$2.40+1.7%$21.00+775.0%-47.6%$16.22MN/A-1.2820Short Interest ↓Positive NewsBIVIBioVie2.6473 of 5 stars$0.85+1.2%$3.00+252.9%+66.9%$15.69MN/A-0.0910Short Interest ↓News Coverage Related Companies and Tools Related Companies Cingulate Competitors Upexi Competitors Equillium Competitors GlycoMimetics Competitors Cocrystal Pharma Competitors Bullfrog AI Competitors Synergy CHC Corp. (Uplisting) Competitors Leap Therapeutics Competitors Edesa Biotech Competitors BioVie Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts